161 related articles for article (PubMed ID: 24525822)
21. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
Rokhlin OW; Glover RB; Guseva NV; Taghiyev AF; Kohlgraf KG; Cohen MB
Mol Cancer Res; 2006 Feb; 4(2):113-23. PubMed ID: 16513842
[TBL] [Abstract][Full Text] [Related]
22. Adenovirus-mediated p53 and ING4 gene co-transfer elicits synergistic antitumor effects through enhancement of p53 acetylation in breast cancer.
Wu J; Zhu Y; Xu C; Xu H; Zhou X; Yang J; Xie Y; Tao M
Oncol Rep; 2016 Jan; 35(1):243-52. PubMed ID: 26530780
[TBL] [Abstract][Full Text] [Related]
23. HIPK2 modulates p53 activity towards pro-apoptotic transcription.
Puca R; Nardinocchi L; Sacchi A; Rechavi G; Givol D; D'Orazi G
Mol Cancer; 2009 Oct; 8():85. PubMed ID: 19828042
[TBL] [Abstract][Full Text] [Related]
24. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
Oh ET; Park MT; Choi BH; Ro S; Choi EK; Jeong SY; Park HJ
Invest New Drugs; 2012 Apr; 30(2):435-42. PubMed ID: 20978925
[TBL] [Abstract][Full Text] [Related]
25. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells.
Hopkins-Donaldson S; Yan P; Bourloud KB; Muhlethaler A; Bodmer JL; Gross N
Oncogene; 2002 Sep; 21(39):6132-7. PubMed ID: 12203125
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
28. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Sampson VB; Vetter NS; Kamara DF; Collier AB; Gresh RC; Kolb EA
PLoS One; 2015; 10(11):e0142704. PubMed ID: 26571493
[TBL] [Abstract][Full Text] [Related]
29. Chloroquine synergizes doxorubicin efficacy in cervical cancer cells through flux impairment and down regulation of proteins involved in the fusion of autophagosomes to lysosomes.
Bano N; Ansari MI; Kainat KM; Singh VK; Sharma PK
Biochem Biophys Res Commun; 2023 May; 656():131-138. PubMed ID: 36963349
[TBL] [Abstract][Full Text] [Related]
30. Synergic CSE1L/CAS, TNFR-1, and p53 apoptotic pathways in combined interferon-gamma/adriamycin-induced apoptosis of Hep G2 hepatoma cells.
Jiang MC; Luo SF; Li LT; Lin CC; Du SY; Lin CY; Hsu YW; Liao CF
J Exp Clin Cancer Res; 2007 Mar; 26(1):91-9. PubMed ID: 17550137
[TBL] [Abstract][Full Text] [Related]
31. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines.
Lee TK; Lau TC; Ng IO
Cancer Chemother Pharmacol; 2002 Jan; 49(1):78-86. PubMed ID: 11855756
[TBL] [Abstract][Full Text] [Related]
32. p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.
Davies C; Hogarth LA; Dietrich PA; Bachmann PS; Mackenzie KL; Hall AG; Lock RB
J Biol Chem; 2011 Oct; 286(43):37639-50. PubMed ID: 21903579
[TBL] [Abstract][Full Text] [Related]
33. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Pitts TM; Morrow M; Kaufman SA; Tentler JJ; Eckhardt SG
Mol Cancer Ther; 2009 Feb; 8(2):342-9. PubMed ID: 19174560
[TBL] [Abstract][Full Text] [Related]
34. Cytoplasmic p21 induced by p65 prevents doxorubicin-induced cell death in pancreatic carcinoma cell line.
Zhou Y; Li G; Ji Y; Liu C; Zhu J; Lu Y
J Biomed Sci; 2012 Feb; 19(1):15. PubMed ID: 22305266
[TBL] [Abstract][Full Text] [Related]
35. Metabolomic Identification of Anticancer Metabolites of Australian Propolis and Proteomic Elucidation of Its Synergistic Mechanisms with Doxorubicin in the MCF7 Cells.
Alsherbiny MA; Bhuyan DJ; Radwan I; Chang D; Li CG
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360606
[TBL] [Abstract][Full Text] [Related]
36. COX-2 inhibitor NS-398 suppresses doxorubicin-induced p53 accumulation through inhibition of ROS-mediated Jnk activation.
Kim J; Shim M
Mol Carcinog; 2016 Dec; 55(12):2156-2167. PubMed ID: 26756900
[TBL] [Abstract][Full Text] [Related]
37. Potential antitumor agent from the endophytic fungus Pestalotiopsis photiniae induces apoptosis via the mitochondrial pathway in HeLa cells.
Chen C; Hu SY; Luo DQ; Zhu SY; Zhou CQ
Oncol Rep; 2013 Oct; 30(4):1773-81. PubMed ID: 23863966
[TBL] [Abstract][Full Text] [Related]
38. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis.
Muñoz-Gámez JA; Martín-Oliva D; Aguilar-Quesada R; Cañuelo A; Nuñez MI; Valenzuela MT; Ruiz de Almodóvar JM; De Murcia G; Oliver FJ
Biochem J; 2005 Feb; 386(Pt 1):119-25. PubMed ID: 15456408
[TBL] [Abstract][Full Text] [Related]
39. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
[TBL] [Abstract][Full Text] [Related]
40. Quercetin enhances the antitumor activity of trichostatin A through up-regulation of p300 protein expression in p53 null cancer cells.
Chuang CH; Chan ST; Chen CH; Yeh SL
Chem Biol Interact; 2019 Jun; 306():54-61. PubMed ID: 30958996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
